As of Jan 29, 2025, Insmed Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $78.0, using a WACC of 9.2% and growth rates of 3.0%.
As of Jan 29, 2025, Insmed Incorporated's Weighted Average Cost of Capital (WACC) is approximately 9.2%.
As of Jan 29, 2025, Insmed Incorporated's Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.